FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096898380> ?p ?o ?g. }

• W3096898380 endingPage "21" @default.
• W3096898380 startingPage "19" @default.
• W3096898380 abstract "Introduction Essential thrombocythemia (ET) and polycythemia vera (PV) patients suffer from various symptoms that worsen quality of life (QOL), yet serial data on symptom changes resulting from therapy are sparse in the literature. Patient questionnaires from 2 large multicenter trials (MPN-RC 111, 112) were used to assess change in symptom burden and QOL over 12 months and impact of baseline symptom burden on subsequent change in ET / PV patients on hydroxyurea (HU) or pegylated interferon alfa-2a (PEG). Methods Trials MPN-RC 111 was a single-arm, open-label, phase II trial evaluating response to PEG in high-risk ET / PV patients with HU resistance/intolerance or splanchnic vein thrombosis (SVT; NCT01259817). MPN-RC 112 was a randomized, open-label, phase III trial comparing response to PEG versus HU in cytoreductive therapy naïve high-risk ET / PV patients diagnosed &lt; 5 years ago (NCT01258856). Measures Patients reported disease-related symptoms via the validated Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF), QOL via the European Organisation for the Research and Treatment of Cancer Core QOL Questionnaire (EORTC QLQ-C30), and (if applicable) PEG-related symptoms (flu-like symptoms, injection site irritation, blurry vision, vision change, flushing) at baseline, 3, 6, 9, and 12 months. Analysis Mixed models assessed mean changes from baseline in the MPN-SAF Total Symptom Score (TSS), MPN-SAF items, QOL, and PEG-related symptoms in MPN-RC 111, 112 PEG, and 112 HU patients. Mixed models also assessed the impact of baseline symptom burden (high [TSS ≥ 20] versus low) on subsequent change in PEG (MPN-RC 111 and 112) and HU patients. Results Patients Of the 135 enrolled MPN-RC 111 patients, 20 with SVT and 1 with no questionnaires were excluded. Of the remaining 114, 64 (56%) / 50 (44%) had ET / PV. Patients were 51% / 48% female. Median age was 65 / 64 years, and median time since diagnosis was 38 / 55 months. 31% / 22% had prior thrombosis, and 19% / 56% had splenomegaly. Of the 168 enrolled MPN-RC 112 patients (82 PEG, 86 HU), 2 with no questionnaires were excluded. Of the remaining 166, 79 (48%) / 87 (52%) had ET / PV. Patients were 50% / 33% female. Median age was 60 / 62 years, and median time since diagnosis was 3 / 3 months. 25% / 29% had prior thrombosis, and 11% / 37% had splenomegaly. Symptoms Questionnaire completion rates ranged from 90 - 99%, 87 - 100%, and 75 - 96% for on-treatment MPN-RC 111, 112 PEG, and 112 HU patients. At baseline, TSS (0 [absent] - 100 [worst imaginable]) and QOL (0 [very poor] - 100 [excellent]) means (SDs) were 19.5 (18.4) and 71.6 (20.1) for MPN-RC 111, 17.0 (13.6) and 67.9 (24.3) for MPN-RC 112 PEG, and 14.6 (11.4) and 73.8 (18.8) for MPN-RC 112 HU patients. On average, MPN-RC 111 patients had significant improvement of TSS, fatigue, abdominal pain, abdominal discomfort, dizziness, numbness, night sweats, and fever; MPN-RC 112 PEG patients had significant worsening of fever; and MPN-RC 112 HU patients had significant worsening of inactivity (no mean changes indicating improvement were observed). PEG patients had significant worsening of PEG-related symptoms. The greatest improvements occurred in the 46 (40%), 27 (33%), and 23 (28%) MPN-RC 111, 112 PEG, and 112 HU patients with high baseline symptom burden. On average, PEG patients with high baseline symptom burden had significant improvement of TSS, fatigue, early satiety, abdominal pain, abdominal discomfort, inactivity, headache, concentration, dizziness, numbness, insomnia, cough, night sweats, itching, bone pain, fever, weight loss, and QOL, while those with low baseline symptom burden had significant worsening of TSS, early satiety, headache, itching, and bone pain. On average, HU patients with high baseline symptom burden had significant improvement of TSS, early satiety, abdominal discomfort, headache, dizziness, numbness, insomnia, itching, and weight loss, while those with low baseline symptom burden had significant worsening of TSS, early satiety, abdominal discomfort, inactivity, concentration, and sexual desire/function (Figures 1 and 2). Conclusions Although no statistical comparisons were made across trials, overall improvements were seen in MPN-RC 111 but not 112. Patients with high baseline symptom burden experienced the greatest improvements in symptom burden and QOL during treatment with PEG or HU, which may explain the improvements seen in the more advanced patients in MPN-RC 111 compared to 112. Disclosures Mascarenhas: Celgene, Prelude, Galecto, Promedior, Geron, Constellation, and Incyte: Consultancy; Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen, and PharmaEssentia: Other: Research funding (institution). Yacoub:Dynavax: Current equity holder in publicly-traded company; Ardelyx: Current equity holder in publicly-traded company; Cara Therapeutics: Current equity holder in publicly-traded company; Hylapharm: Current equity holder in private company; Incyte: Speakers Bureau; Agios: Honoraria, Speakers Bureau; Novartis: Speakers Bureau; Roche: Other: Support of parent study and funding of editorial support. Hoffman:Protagonist: Consultancy; Forbius: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Dompe: Research Funding. Silver:PharmaEssentia: Speakers Bureau. Mesa:Bristol Myers Squibb: Research Funding; Incyte: Research Funding; AbbVie: Research Funding; Samus Therapeutics: Research Funding; Genentech: Research Funding; CTI BioPharma: Research Funding; Promedior: Research Funding; Sierra Oncology: Consultancy; LaJolla Pharmaceutical Company: Consultancy; Novartis: Consultancy." @default.
• W3096898380 created "2020-11-09" @default.
• W3096898380 creator A5006372952 @default.
• W3096898380 creator A5035746810 @default.
• W3096898380 creator A5038693643 @default.
• W3096898380 creator A5039057642 @default.
• W3096898380 creator A5040941721 @default.
• W3096898380 creator A5042381475 @default.
• W3096898380 creator A5064707298 @default.
• W3096898380 creator A5069072959 @default.
• W3096898380 creator A5071257161 @default.
• W3096898380 creator A5072336042 @default.
• W3096898380 creator A5090009905 @default.
• W3096898380 date "2020-11-05" @default.
• W3096898380 modified "2023-10-16" @default.
• W3096898380 title "Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials" @default.
• W3096898380 doi "https://doi.org/10.1182/blood-2020-142817" @default.
• W3096898380 hasPublicationYear "2020" @default.
• W3096898380 type Work @default.
• W3096898380 sameAs 3096898380 @default.
• W3096898380 citedByCount "0" @default.
• W3096898380 crossrefType "journal-article" @default.
• W3096898380 hasAuthorship W3096898380A5006372952 @default.
• W3096898380 hasAuthorship W3096898380A5035746810 @default.
• W3096898380 hasAuthorship W3096898380A5038693643 @default.
• W3096898380 hasAuthorship W3096898380A5039057642 @default.
• W3096898380 hasAuthorship W3096898380A5040941721 @default.
• W3096898380 hasAuthorship W3096898380A5042381475 @default.
• W3096898380 hasAuthorship W3096898380A5064707298 @default.
• W3096898380 hasAuthorship W3096898380A5069072959 @default.
• W3096898380 hasAuthorship W3096898380A5071257161 @default.
• W3096898380 hasAuthorship W3096898380A5072336042 @default.
• W3096898380 hasAuthorship W3096898380A5090009905 @default.
• W3096898380 hasBestOaLocation W30968983801 @default.
• W3096898380 hasConcept C126322002 @default.
• W3096898380 hasConcept C141071460 @default.
• W3096898380 hasConcept C159110408 @default.
• W3096898380 hasConcept C203014093 @default.
• W3096898380 hasConcept C2522874641 @default.
• W3096898380 hasConcept C2776408679 @default.
• W3096898380 hasConcept C2776461080 @default.
• W3096898380 hasConcept C2778837598 @default.
• W3096898380 hasConcept C2779951463 @default.
• W3096898380 hasConcept C2780040827 @default.
• W3096898380 hasConcept C2781057849 @default.
• W3096898380 hasConcept C71924100 @default.
• W3096898380 hasConcept C90924648 @default.
• W3096898380 hasConceptScore W3096898380C126322002 @default.
• W3096898380 hasConceptScore W3096898380C141071460 @default.
• W3096898380 hasConceptScore W3096898380C159110408 @default.
• W3096898380 hasConceptScore W3096898380C203014093 @default.
• W3096898380 hasConceptScore W3096898380C2522874641 @default.
• W3096898380 hasConceptScore W3096898380C2776408679 @default.
• W3096898380 hasConceptScore W3096898380C2776461080 @default.
• W3096898380 hasConceptScore W3096898380C2778837598 @default.
• W3096898380 hasConceptScore W3096898380C2779951463 @default.
• W3096898380 hasConceptScore W3096898380C2780040827 @default.
• W3096898380 hasConceptScore W3096898380C2781057849 @default.
• W3096898380 hasConceptScore W3096898380C71924100 @default.
• W3096898380 hasConceptScore W3096898380C90924648 @default.
• W3096898380 hasIssue "Supplement 1" @default.
• W3096898380 hasLocation W30968983801 @default.
• W3096898380 hasOpenAccess W3096898380 @default.
• W3096898380 hasPrimaryLocation W30968983801 @default.
• W3096898380 hasRelatedWork W2130932687 @default.
• W3096898380 hasRelatedWork W2490277447 @default.
• W3096898380 hasRelatedWork W2563770732 @default.
• W3096898380 hasRelatedWork W2596612621 @default.
• W3096898380 hasRelatedWork W2903749170 @default.
• W3096898380 hasRelatedWork W2965473563 @default.
• W3096898380 hasRelatedWork W2976693482 @default.
• W3096898380 hasRelatedWork W2981069188 @default.
• W3096898380 hasRelatedWork W3117992776 @default.
• W3096898380 hasRelatedWork W3197539263 @default.
• W3096898380 hasVolume "136" @default.
• W3096898380 isParatext "false" @default.
• W3096898380 isRetracted "false" @default.
• W3096898380 magId "3096898380" @default.
• W3096898380 workType "article" @default.